| |
Wednesday, May 21st |
 |
|
8:00am-9:30am |
Contributed Podium
Presentations – Session III |
|
|
|
ADHERENCE |
|
Moderator: Beth
Devine PharmD, MBA, Research Assistant Professor, Associate
Director, Pharmaceutical Outcomes Research and Policy Program,
Department of Pharmacy, University of Washington, Seattle, WA, USA |
|
AD1 |
NON-PROCUREMENT OF
PRESCRIPTION MEDICATIONS DUE TO COST IN MEDICARE BENEFICIARIES: RESULTS
FROM THE HEALTH AND RETIREMENT STUDY
Ellis JJ, Kirking DM, Erickson SR,
University of Michigan, Ann Arbor, MI, USA |
|
AD2 |
MEDICATION TREATMENT
PERSISTENCE OF OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS IN A
CALIFORNIA MEDICAID PROGRAM AND THE BENEFIT OF THEIR REFILL ADHERENCE ON
URINARY TRACK INFECTION
Yu YF1, Yu AP2, Ahn J1, Nichol MB1, 1University of
Southern California, Los Angeles, CA, USA; 2USC School of Pharmacy, Los
Angeles, CA, USA |
|
AD3 |
PREDICTIVE MODEL OF
MEDICATION ADHERENCE IN CARDIOVASCULAR DISEASE
Chen KS1, Leslie RS1, Chang E1, Fairchild C2, 1Prescription
Solutions, Costa Mesa, CA, USA; 2Bristol-Myers Squibb, Plainsboro, NJ,
USA |
|
AD4 |
A TIME-VARYING
SURVIVAL MODEL FOR THE ASSOCIATION OF ADHERENCE WITH HMG-COA INHIBITORS
TO THE RISK OF ADVERSE EVENTS
Yu AP, Nichol MB, University of Southern California, Los Angeles,
CA, USA |
|
|
DRUG POLICY |
|
|
Moderator:
Kathleen A. Weis DrPH, PhD, MSN, ENP, Director, Outcomes
Research, Pfizer Pharmaceuticals Group, Pfizer Inc., New York, NY, USA |
|
DP1 |
RELATIONSHIP BETWEEN
DIRECT-TO-CONSUMER ADVERTISING AND PRODUCT INNOVATIVENESS
Fuldeore M, Krueger K, Auburn University, Auburn, AL, USA |
|
DP2 |
ECONOMIC IMPACT OF
PROZAC® PATENT EXPIRATION AND THE 180-DAY GENERIC FLUOXETINE EXCLUSIVITY
IN A PUBLICLY-FINANCED PRESCRIPTION PROGRAM
Punjabi SS1, Johnsrud MT1, Conner C2, 1The University of
Texas at Austin, Austin, TX, USA; 2Pfizer Inc, Milwaukee, WI, USA |
|
DP3 |
PHYSICIAN ATTITUDE
TOWARD ACADEMIC DETAILING AND OTHER DRUG COST-CONTAINMENT STRATEGIES IN
A STATE HEALTH INSURANCE PROGRAM
Madhavan SS1, Susman T2, Shimer P2, Joseph F2, Sundaram M1,
Kamat S1, D'Souza AO1, 1West Virginia University, Morgantown, WV,
USA; 2West Virginia Public Employees Insurance Agency, Charleston, WV,
USA |
|
DP4 |
ARE SICK PEOPLE LESS
RESPONSIVE TO PRESCRIPTION BENEFIT CHANGES?
Xiao Q, Marks AS, Patel H, Caremark Inc, Northbrook, IL, USA
|
|
|
DIABETES |
|
|
Moderator:
Phillip Sarocco RPh, MSc, Director of Health Economics and
Outcomes Research, Aventis Pharmaceuticals, Parsippany, NJ, USA |
|
DB1 |
IMPACT OF PARTICIPANT
COST-SHARE ON COMPLIANCE RATES IN PARTICIPANTS WITH DIABETES
Moore JM, Marks AS, Kassulke JP, Patel H, Caremark, Inc,
Northbrook, IL, USA |
|
DB2 |
INCOME DISPARITY IN
DIFFUSION OF ORAL DIABETES THERAPY 1999-2001
Snyder SE1, Proveaux WJ2, Mullins CD1, 1University of Maryland
School of Pharmacy, Baltimore, MD, USA; 2CareFirst BlueCross BlueShield,
Baltimore, MD, USA |
|
DB3 |
ORAL ANTIHYPERGLYCEMIC
MEDICATION NON-ADHERENCE AND SUBSEQUENT HOSPITALIZATION AMONG PERSONS
WITH TYPE 2 DIABETES
Lau DT1, Nau DP2, 1University of Michigan /Pfizer Inc, Ann Arbor,
MI, USA; 2University of Michigan, Ann Arbor, MI, USA |
|
DB4 |
MULTI-SITE EVALUATION
OF DIABETES DISEASE MANAGEMENT PROGRAMS USING THE DIABETES MANAGEMENT
EVALUATION TOOL (DMET)
Sikirica M, Hartmann C, Goldfarb N, Crawford A, Nash DB, Thomas
Jefferson University, Philadelphia, PA, USA |
|
|
AGING |
|
|
Moderator:
Sonali Shah RPh, MS,
MBA, Manager, Pfizer, Hoboken, NJ, USA |
|
AG1 |
CHANGES IN FUNCTIONAL
DISABILITY LEVELS AND MEDICAL EXPENDITURES AMONG ELDERLY PERSONS
Kamal-Bahl S, Stuart B, Briesacher B, Doshi J, University of
Maryland, Baltimore, MD, USA |
|
AG2 |
RELATIONSHIP BETWEEN
QUALITY OF LIFE AND COGNITIVE STATUS AMONG LONG-TERM CARE FACILITY
RESIDENTS IN WEST VIRGINIA: A PILOT STUDY
Johnson JK1, Scott VG1, Mody RR1, Atkinson WL2, 1West Virginia
University, Morgantown, WV, USA; 2Aegis Health, Lewisburg, WV, USA
|
|
AG3 |
A COMPARATIVE COST
ANALYSIS OF ALZHEIMER’S DISEASE VERSUS VASCULAR DEMENTIA
Menzin J1, Boulanger L1, deFriesse R1, Friedman M1, Neumann P2,
1Boston Health Economics, Inc, Waltham, MA, USA; 2Harvard School of
Public Health, Boston, MA, USA |
|
AG4 |
INAPPROPRIATE DRUG
PRESCRIBING IN OUTPATIENT CARE FOR THE ELDERLY: THE CASE OF POTENTIALLY
HARMFUL DRUG-DRUG AND DRUG-DISEASE COMBINATIONS
Zhan C1, Correa-de-Araujo R1, Wickizer S2, Miller MR3, Bierman
A1, 1AHRQ, Rockville, MD, USA; 2NCI, Frederick, MD, USA; 3Johns
Hopkins Childrens Center, Baltimore, MD, USA |
|
|
|
9:30am-10:15am |
Break |
|
Break sponsored by University Of Maryland |
|
|
|
10:10am-12:00pm |
Third Plenary Session |
|
|
| |
Introductions: Peter
Davey MD, FRCP, 2002-2003 ISPOR President and Head of
Pharmacoeconomics, University of Dundee, Dundee, Scotland, UK
|
|
10:15am-10:30am |
ISPOR Contributed Research
Awards Presentations |
| |
ISPOR Best Contributed Poster Presentations
GENERAL• NEW INVESTIGATOR • STUDENT (up to 3 awards in each category)
ISPOR Best Contributed PODIUM Presentations
GENERAL• NEW INVESTIGATOR • STUDENT (up to 3 awards in each category)
Presented by ISPOR Contributed Papers Awards Task Force Co-Chairs:
Les Noe RPh, MPA, Vice President,
Ovation Research Group, Highland Park, IL, USA and
C. Daniel Mullins PhD, Associate Professor, University of
Maryland, School of Pharmacy, Baltimore, MD, USA
|
| 10:30am-12:00pm |
The
Role of Outcomes Research in a Medicare Drug Benefit Program
Moderator: Daniel Mendelson, Managing Director, The Health
Strategies Consultancy LLC, Washington, DC, USA
Speaker: Kenneth E. Thorpe PhD, Professor
and Chair of Health Policy & Management, Emory University, Atlanta,
Georgia, USA
Speaker: Jean Paul Gagnon PhD, RPh,
Director, Public Policy, Aventis Pharmaceuticals, Inc, Bridgewater, NJ,
USA |
|
|
| 12:00am-2:00pm |
Leadership Luncheon (by
invitation only) |
|
|
|
